출생부터 18세 미만까지의 피험자에서 CRBSI에 대한 안전성과 시간을 평가하기 위한 공개 라벨 이중 연구
출생부터 18세 미만 신부전이 있는 피험자에서 혈액투석을 통해 카테터 관련 혈류 감염(CRBSI)에 대한 안전성과 시간을 평가하기 위한 오픈 라벨, 투암(DefenCath® 대 기관 표준 치료) 연구 중심 정맥 카테터
This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 4단계
확장된 액세스
확장된 액세스
더 이상 사용할 수 없음
- 사용 가능: 현재 이 연구 치료에 대해 확장된 액세스가 가능하며 임상 연구에 참여하지 않은 환자는 약물, 생물학적 제제 또는 의료 기기에 액세스할 수 있습니다. 연구 중입니다.
- 더 이상 사용할 수 없음: 이전에는 이 개입에 대해 확장된 액세스를 사용할 수 있었지만 현재 사용할 수 없으며 앞으로도 사용할 수 없습니다.
- 일시적으로 사용할 수 없음: 현재 이 개입에 대해 확장된 액세스를 사용할 수 없지만 향후 사용할 수 있을 것으로 예상됩니다.
- 마케팅 승인: 개입 대중이 사용할 수 있도록 미국 식품의약국(FDA)의 승인을 받았습니다.
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Liz Hurlburt
- 전화번호: 9085179500
- 이메일: lhurlburt@cormedix.com
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- Children's of Alabama/University of Alabama
-
연락하다:
- Sahar Fathallah-Shaykh, MD
- 전화번호: 205-638-9781
- 이메일: sfshaykh@uabmc.edu
-
연락하다:
- Susan Keeling
- 전화번호: 205-638-2792
- 이메일: skeeling@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, 미국, 85016
- 모병
- Phoenix Children's Hospital
-
연락하다:
- Anjali Nayak, MD
- 전화번호: 602-933-0574
- 이메일: anayak@phoenixchildrens.com
-
연락하다:
- Elisbeth Reyes
- 전화번호: 732-788-5775 732-788-5775
- 이메일: ereyes1@phoenixchildrens.com
-
-
California
-
Palo Alto, California, 미국, 94304
- 모병
- Stanford
-
연락하다:
- Shina Menon, MD
- 전화번호: 650-721-5807
- 이메일: shinam@stanford.edu
-
연락하다:
- Amanda Tapia
- 전화번호: 831-710-6196
- 이메일: amandatapia@stanford.edu
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Nemours Children's Hospital - DE
-
연락하다:
- Jessica Rayfield
- 전화번호: 302-298-2777
- 이메일: jessica.rayfield@nemours.org
-
연락하다:
- Ali M Onder, MD
- 전화번호: 302-651-4426
- 이메일: Alimirza.Onder@nemours.org
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
연락하다:
- Kenneth Lieberman, MD
- 전화번호: 551-996-8228
- 이메일: Kenneth.lieberman@hmhn.org
-
연락하다:
- Sabrina Kdiry, RNC
- 전화번호: 551-996-6588
- 이메일: Sabrina.kdiry@hmhn.org
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Health Care System
-
연락하다:
- Robert Gillespie, MD
- 전화번호: 817-879-3500
- 이메일: Robert.Gillespie@cookchildrens.org
-
연락하다:
- Jamie Chapman
- 전화번호: 817-264-2712
- 이메일: Jamie.Chapman@cookchildrens.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- All participants must be < 18 years of age and must meet the following inclusion criteria:
- The investigator, or a person designated by the investigator, will obtain written informed consent from each study participant's legal guardian and the participant's assent, when applicable, before any study-specific activity is performed. All legal guardians should be fully informed, and participants should be informed to the fullest extent possible, about the study in language and terms they are able to understand.
- A legal guardian or primary caregiver must be available to help the study-site personnel ensure follow up; accompany the participant to the study site on each assessment day according to the schedule of activities (SoA) (e.g., able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures); consistently and consecutively be available to provide information on the participant during the scheduled study visits; accurately and reliably dispense study intervention as directed.
- The participant has kidney failure and undergoes chronic hemodialysis (HD) at least 2 times per week.
- The participant has an HD central venous catheter (CVC) and is placed in a jugular or subclavian vein.
- The participant has demonstrated the ability to achieve an appropriate minimum blood flow (Qb) for the participant's relative age and weight for at least 2 consecutive dialysis sessions to enable successful HD.
- The participant is likely to require the use of a CVC for at least 60 days, based on clinical assessment.
- The participant is willing to comply with specified follow-up evaluations and prescribed dialysis therapy.
- The participant is not expected to expire within 180 days, based on clinical assessment.
- Female participants of childbearing potential:
- Must agree to abide by contraception requirements, must not be lactating, and avoid pregnancy during study participation from the first Screening visit until 30 days after the last administration of study treatment.
- Must commit to an additional method of birth control in addition to male partners agreeing to use condoms with spermicide, throughout the study including for at least 30 days after the last administration of study treatment:
- True abstinence: Refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable).
Combined (containing estrogen and progestogen) hormonal birth control (oral, intravaginal, injectable, or transdermal) associated with inhibition of ovulation initiated at least 30 days before dose administration.
- Progestogen only hormonal birth control (oral, injectable, or implantable) associated with inhibition of ovulation initiated at least 30 days before study dose administration.
- Bilateral tubal occlusion/ligation.
- Intrauterine device.
- Intrauterine hormone releasing system.
- Vasectomized partner.
- NOTE: If the childbearing potential changes after start of the study (e.g., a premenarchal female participant experiences menarche) or the risk of pregnancy changes (e.g., a female participant who is not heterosexually active becomes active), the participant must discuss this with the investigator, who should determine if a female participant must begin a highly effective method of contraception, or a male participant must use a condom. If reproductive status is questionable, additional evaluation should be considered.
- Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms and spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last administration of study treatment.
Exclusion Criteria:
- Any participant who is currently receiving systemic antibiotics. Topical antibiotic use is permitted.
- Visible evidence of compromised skin integrity is present at the catheter exit site or evidence of a catheter exit site infection.
- The participant has received any thrombolytic treatment (i.e., tissue plasminogen activator [tPA] - Cathflo®), not as part of the institution's standard of care for patency management, in their current catheter within 30 days of randomization.
- The fill volume of catheter lumen(s) is unknown or cannot be determined.
- The participant uses any type of antimicrobial-coated or heparin-coated catheter.
- Documented chronic bleeding diathesis, active or recurrent bleeding within 30 days prior to randomization.
- Documented history of an atrial thrombus or known hypercoagulable state.
- The participant has open, non-healing skin ulcers.
- Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.
- The participant has current requirement for systemic chemotherapy and/or immunosuppression and absolute neutrophil count <500 cells/µL that occurred in the past 4 weeks.
- An active malignancy that either in and of itself or by virtue of its treatment with chemotherapy or biologic therapy results in neutropenia, leukopenia and/or immunosuppression.
- Known allergy or absolute contraindication to taurolidine, citrate, or heparin, or a history of heparin induced thrombocytopenia (HIT).
- Unstable malignancy.
- Cirrhosis with encephalopathy.
- The participant is currently taking another medication with known systemic drug interaction with taurolidine, citrate, or heparin.
- The participant is anticipated to receive a renal transplant within 90 days (participants can be on the transplant list, but a participant with a known or anticipated transplant date within the next 90 days should be excluded).
- The participant has a clinically significant cardiac rhythm or functional disorder.
- The participant has severe hypoxemia, respiratory acidosis, asphyxia, or hypotension prior to randomization based on assessment of the investigator.
- Any other medical condition which renders the participant unable to or unlikely to complete the study, or which would interfere with optimal participation in the study or produce significant risk to the participant.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: 제어
|
Site specific standard of care |
|
실험적: 디펜캐스®
|
for central venous catheter instillation use
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to first clinical diagnosis of Catheter-related Bloodstream Infections (CRBSI)
기간: Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
To demonstrate the effectiveness of DefenCath as a catheter lock solution (CLS) for prevention of CRBSI in pediatric participants receiving chronic hemodialysis (HD) through a central venous catheter (CVC) for the treatment of kidney failure. |
Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
|
Descriptive analysis characterizing the relative rates of deaths, AEs, and SAEs
기간: Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
To demonstrate safety of DefenCath as a CLS in pediatric participants receiving chronic HD through a CVC for the treatment of kidney failure |
Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to catheter removal due to CRBSI
기간: Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
To evaluate the catheter removal due to CRBSI in pediatric participants who are receiving chronic HD through a CVC for kidney failure. |
Patient has been randomized and has received at least 1 instillation of the assigned lock solution, and has received confirmed diagnosis of CRBSI (up to 13 months)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PEDI-LOCK
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .